Arrowhead Pharmaceuticals, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Amgen is no stranger to the heavy lifting required to get a new treatment for cardiovascular diseases off the ground, since its LDL cholesterol-lowering PCSK9 inhibitor Repatha (evolocumab) was not an